JOINN Biologics US Inc.’s Post

Live webinar! March 20th, 2024 @ 11 AM ET Impurities can induce immune reactions in patients, forcing scientists to restart process development. Thus, detecting and removing biopharmaceutical impurities such as host cell proteins is important for biotherapeutic development and production, and necessary for maintaining drug efficacy and ensuring patient safety. In this webinar brought to you by Cytiva, Andrew Hamilton and Joe Hirano will discuss how to identify, detect, and measure impurities in biologics manufacturing. Register here #AD: https://ow.ly/cKoC50QEbNV

In the ever-advancing world of biopharmaceutical research, cell line development (CLD) is taking the center stage across various application areas. It's playing a pivotal role in the development of biotherapeutics, encompassing monoclonal antibodies, vaccines, and biologics. Researchers, in their pursuit of improving the productivity of biopharmaceuticals, have turned to cell-based assays and the screening of different clones. However, the traditional manual screening methods used for CLD are both time-consuming and labor-intensive. To alleviate these challenges, CYTENA and Biosero have collaborated to offer a turnkey automation solution: the C.STATION. The C.STATION manages the entire CLD process, from single-cell cloning to selecting and scaling the best-performing clones. Watch the video to learn how this bioconvergant solution streamlines the CLD workflow, minimizing manual labor while enhancing reproducibility and traceability.

In Case You Missed It: "Advanced Analytical Strategies: From Protein Structure Characterization to Potency Assessment for Challenging Biologic Modalities" In the rapidly evolving landscape of biologics, especially for new modalities like antibody drug conjugates (ADCs) and bispecific/multi-specific antibodies, detailed product characterization evaluation and appropriate potency assessment are crucial for ensuring product quality control and fulfilling regulatory requirement. Our webinar will feature two engaging topics: Deciphering Protein Structure: Advancing Biologics Development by Product Characterization and Revealing the Biologics Efficacy: Advanced Strategies for Potency Assay Development for Multi-Specific Drugs. View on demand: https://lnkd.in/eWHxA3vg

Webinar - Mitigating Biopharmaceutical Impurities in Monoclonal Antibody Therapeutic Manufacturing Wednesday, March 20th, 2024 Biopharmaceutical impurities such as host cell proteins can delay biologics development and production. These elements can have immunogenic effects in patients, forcing scientists to restart process development. Thus, detecting and removing biopharmaceutical impurities is necessary for maintaining drug efficacy and ensuring patient safety. In this webinar brought to you by Cytiva, Andrew Hamilton and Joe Hirano will discuss how to identify, detect, and measure impurities in biologics manufacturing. https://lnkd.in/ga_TmW_Q

In Case You Missed It: "Advanced Analytical Strategies: From Protein Structure Characterization to Potency Assessment for Challenging Biologic Modalities" In the rapidly evolving landscape of biologics, especially for new modalities like antibody drug conjugates (ADCs) and bispecific/multi-specific antibodies, detailed product characterization evaluation and appropriate potency assessment are crucial for ensuring product quality control and fulfilling regulatory requirement. Our webinar features two engaging topics: Deciphering Protein Structure: Advancing Biologics Development by Product Characterization and Revealing the Biologics Efficacy: Advanced Strategies for Potency Assay Development for Multi-Specific Drugs. View on demand: https://lnkd.in/eWHxA3vg

Antibody Therapeutics (2022 CiteScore: 6.4), the official journal of our society, recently published a mini-review article entitled as “Further accelerating biologics development from DNA to IND: the journey from COVID-19 to non-COVID-19 programs”. The corresponding authors are Sheng (Sam) Zhang and Weichang Zhou from WuXi Biologics. The COVID-19 pandemic has propelled unprecedented speed to clinic for neutralizing COVID-19 monoclonal antibodies with demonstrated product quality and consistency. Innovative acceleration strategies used inCOVID-19 programs can be considered and holistically applied in biologics development of all disease areas to further shorten CMC timeline. #antibodies #antibody #antibodytherapeutics #mabs #mab #antibodydiscovery #biologics #cmc #processdevelopment

Our continuous commitment to solve development and manufacturing challenges of complex mAbs and deliver high quality biologics to global patients in need. Kemwell Biopharma and RevOpsis Therapeutics enter into strategic manufacturing partnership to expedite development of Novel Multispecific biologics  candidate RO-104. Under this partnership, Kemwell will manufacture RO-104, a novel tri-specific biologic designed to target the three dominant angiogenic pathways (VEGF-A, VEGF-C, Ang-2) for treating nAMD, a leading cause of blindness worldwide. This collaboration leverages Kemwell’s well-established manufacturing excellence and RevOpsis' innovative Rev-Mod platform to expedite the development of novel multispecific biologics and provides RevOpsis a critical biologics development solution to rapidly transition from pre-clinical activities to first-in-human clinical trials, expediting the development of RO-104 and the broader platform. Please check the link for more info https://shorturl.at/18g1B . . #news #collaboration #complex mAbs #multispecific biologics #RO-104

Highly recommend this excellent review article. One of the two corresponding authors is Dr. Sheng (Sam) Zhang, an Executive Director and Head of Cell Line Development at WuXi Biologics.

Register today for "Advanced Analytical Strategies: From Protein Structure Characterization to Potency Assessment for Challenging Biologic Modalities" In the rapidly evolving landscape of biologics, especially for new modalities like antibody drug conjugates (ADCs) and bispecific/multi-specific antibodies, detailed product characterization evaluation and appropriate potency assessment are crucial for ensuring product quality control and fulfilling regulatory requirement. Our webinar will feature two engaging topics: Deciphering Protein Structure: Advancing Biologics Development by Product Characterization and Revealing the Biologics Efficacy: Advanced Strategies for Potency Assay Development for Multi-Specific Drugs. To learn more, visit the registration page and save your spot today. Register here: https://lnkd.in/eVKhuZYm

Please use below link to register for the upcoming workshop on Therapeutic Drug Monitoring of Biologics.